• N/A
    Market Cap
  • -50.92%
    1-Year Change
  • Drug Manufacturers - General
    Industry
Annual
Quarterly
12/31/2025
Income Statement
Total Operating Revenue
1.2B
N/A
Cost of Revenue
N/A
N/A
Gross Profit
1.2B
N/A
Sales and Marketing Expense
167,000
N/A
Research and Development Expense
-653,000
N/A
Depreciation and Amortization Expense
N/A
N/A
Total Operating Expenses
4.9M
N/A
Operating Profit
-4.9M
N/A
Interest Income
N/A
N/A
Interest Expense
N/A
N/A
Interest Income and Expense and Net
0
N/A
Total Nonoperating Income and Expense
N/A
N/A
Income before Taxes
-4.9M
N/A
Income Taxes
N/A
N/A
Extraordinary Items
N/A
N/A
Net Income
-5.8M
N/A
Net Income from Continuing Operations Applicable to Common
-5.8M
N/A
Basic EPS and Net Income
-0.72
N/A
Diluted EPS and Net Income
-0.72
N/A
Basic Weighted Average Shares
8.0M
N/A
Diluted Weighted Average Shares
8.0M
N/A
Balance Sheet
Cash and Cash Equivalents
1.2M
N/A
Short-Term Investments
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
1.2M
N/A
Total Current Assets
4.9M
N/A
Accumulated Depreciation
N/A
N/A
Property and Plant and Equipment and Net
14,000
N/A
Total Long-Term Assets
14,000
N/A
Total Assets
5.0M
N/A
Income Taxes Payable
N/A
N/A
Total Short-Term Debt
560,000
N/A
Total Current Liabilities
2.2M
N/A
Total Long-Term Debt
N/A
N/A
Total Long-Term Liabilities
73,000
N/A
Total Liabilities
2.2M
N/A
Retained Earnings
-18.5M
N/A
Total Stockholders Equity
N/A
N/A
Total Shares Outstanding
N/A
N/A
Cash Flow
Cash from Operating Activities
-4.9M
N/A
Capital Expenditures
14,000
N/A
Cash from Investing Activities
-3.0M
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
8.9M
N/A
Financials Ratio
Gross Margin
N/A
N/A
Operating Margin
N/A
N/A
Return on Assets
N/A
N/A
Return on Equity
N/A
N/A
Revenue Growth
N/A
N/A
Current Ratio
N/A
N/A
Cash Ratio
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow